Knocking down low molecular weight protein tyrosine phosphatase (LMW-PTP) reverts chemoresistance through inactivation of Src and Bcr-Abl proteins.
The development of multidrug resistance (MDR) limits the efficacy of continuous chemotherapeutic treatment in chronic myelogenous leukemia (CML). Low molecular weight protein tyrosine phosphatase (LMW-PTP) is up-regulated in several cancers and has been associated to poor prognosis. This prompted us...
Main Authors: | Paula A Ferreira, Roberta R Ruela-de-Sousa, Karla C S Queiroz, Ana Carolina S Souza, Renato Milani, Ronaldo Aloise Pilli, Maikel P Peppelenbosch, Jeroen den Hertog, Carmen V Ferreira |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22957062/?tool=EBI |
Similar Items
-
Src-Kinasen als Mediatoren Bcr-Abl-induzierter Leukämien
by: Warmuth, Markus
Published: (2002) -
In vivo detection of the BCR/ABL1 protein
by: Chen, Ying
Published: (2006) -
LMW-PTP targeting potentiates the effects of drugs used in chronic lymphocytic leukemia therapy
by: Nagaja Capitani, et al.
Published: (2019-03-01) -
Characterization and substrate identification of LMW-PTP Wzb in Klebsiella pneumoniae NTUH-K2044
by: Tung-Li Hsu, et al.
Published: (2008) -
Computational and structure-guided design of phosphoinositide substrate specificity into the tyrosine specific LMW-PTP enzyme.
by: Eyong Egbe, et al.
Published: (2020-01-01)